Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III ...

AstraZeneca Vietnam has been honoured in the Outstanding CSR Activities category at the 2025 Top 50 Corporate Sustainability ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

Following a successful patent defense case upheld by China’s IP authority, AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai, said ...

New class of Eureka Fellows selected for their outstanding efforts to build a healthier, more equitable world and will receive support to amplify their sustainability impact in Canada and around ...

In recent years successive governments have sought to close down free speech. If we are to avoid the enslavement of our ...

With the company's market capitalization at Rs 2,292.62 Crore, this dividend payout reflects AstraZeneca's commitment to returning value to its shareholders.

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

The biggest fallers on the FTSE 100 were AstraZeneca, down 124.00p at 10,312p, British American Tobacco, down 60.00p at 3,813 ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives, namely ...